01—Abstract
Summary
Summary of the 10-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc's 2023 Form 10-K reports Portfolio Receipts of $3.05 billiona, up from $2.79 billion in 2022, with royalty receipts of $2.45 billion and milestones and other contractual receipts of $599.3 million.
The company describes itself as the largest buyer of biopharmaceutical royalties and deployed $2.2 billionb of cash in 2023 to acquire royalties, milestones and other contractual receipts. Net income attributable to Royalty Pharma plc rose to $1.13 billion in 2023 from $42.8 million in 2022, driven largely by the absence of 2022's $615.8 million financial royalty asset impairment and a $366.2 million other income, net line item that included $230.8 million of gains on available for sale debt securities. Operating income was $1.49 billion versus $307.1 million a year earlier.
Cash generation and shareholder returns were strong. Net cash provided by operating activities was $2.99 billionc, versus $2.14 billion in 2022, helped by a $475.0 million Zavzpret milestone. The company repaid $1.0 billion of senior unsecured notes in September 2023, paid $358.3 million in dividends ($0.20 per quarter), and repurchased Class A shares for $304.8 million.
Total senior unsecured notes were $6.3 billiond at year end, with $1.8 billion available under the revolving credit facility, and the company reported compliance with its financial covenants. Investors should note that reported GAAP results are volatile because most royalties are accounted for as financial assets under the effective interest method.
The 2023 provision for changes in expected cash flows was $560.7 million expense, and the filing states that Vertex's cystic fibrosis franchise accounted for 36% of total income and other revenues. The filing also highlights concentration risk: the top five product franchises represented 66% of royalty receipts in 2023, and the company is externally managed by RP Management, LLC, with Operating and Personnel Payments set at 6.5% of Portfolio Receipts.
02—Key points
Key Highlights
- Portfolio Receipts rose to $3.05 billion in 2023 from $2.79 billion in 2022, and the company deployed $2.2 billion of cash to acquire royalties, milestones and other contractual receipts.
- Net income attributable to Royalty Pharma plc was $1.13 billion in 2023, compared with $42.8 million in 2022, which included a $615.8 million financial royalty asset impairment.
- Net cash provided by operating activities was $2.99 billion in 2023, up from $2.14 billion, including a $475.0 million milestone tied to FDA approval of Zavzpret.
- The company returned capital to shareholders in 2023 through $358.3 million of dividends and $304.8 million of Class A share repurchases, under a $1.0 billion authorization.
- Vertex's cystic fibrosis franchise was the largest contributor, accounting for 36% of total income and other revenues, and the top five product franchises represented 66% of royalty receipts.
- Senior unsecured notes totaled $6.3 billion at December 31, 2023 after a $1.0 billion repayment in September 2023, and $1.8 billion of revolving commitments were available.
- Reported GAAP income is volatile because most royalties are financial assets under the effective interest method; the 2023 provision for changes in expected cash flows was a $560.7 million expense.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 15, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $2.35B$2.24B | +5.2% |
| R&D Expenses | $52.00M$177.11M | −70.6% |
| Operating Expenses | $862.40M$1.93B | −55.3% |
| Operating Income | $1.49B$307.06M | +385.9% |
| Interest Expense | $187.19M$187.96M | −0.4% |
| Net Income | $1.13B$42.83M | +2549.5% |
| EPS (Basic) | $2.54$0.10 | +2440.0% |
| EPS (Diluted) | $2.53$0.10 | +2430.0% |
| Shares Outstanding (Basic) | 447.60M437.96M | +2.2% |
| Shares Outstanding (Diluted) | 602.90M437.97M | +37.7% |
05—Questions
Frequently Asked Questions
What drove the increase in Royalty Pharma's net income in 2023?
Net income attributable to Royalty Pharma plc rose to $1,134.8 million in 2023 from $42.8 million in 2022. The filing attributes the change largely to the absence of the $615.8 million financial royalty asset impairment recorded in 2022, together with higher income from financial royalty assets of $2,197.8 million and other income, net of $366.2 million, which included $230.8 million of gains on available for sale debt securities.
What are Royalty Pharma's main sources of royalty revenue?
Vertex's cystic fibrosis franchise was the largest source, with 2023 royalty receipts of $771 million and end market sales of $9,869 million. The filing states that the top five product franchises accounted for 66% of royalty receipts in 2023, and that no individual product accounted for more than 23% of Portfolio Receipts.
How is Royalty Pharma funding its growth and shareholder returns?
The company funds acquisitions primarily from royalty cash flows, supplemented by debt. It deployed $2.2 billion in 2023, repaid $1.0 billion of senior unsecured notes, and reports $1.8 billion of available revolving commitments. It also paid $358.3 million in dividends and repurchased shares for $304.8 million, with a $1.0 billion repurchase program authorized through June 23, 2027.
Why can reported earnings differ from cash receipts?
Most royalties are accounted for as financial assets measured at amortized cost under the effective interest method. Changes in sell-side analyst sales forecasts can produce non-cash provision expenses or income, so the filing notes there is no direct correlation between income from financial royalty assets and royalty receipts. In 2023 the provision for changes in expected cash flows was $560.7 million expense.
What risks does the filing highlight for investors?
The filing highlights reliance on a limited number of products, dependence on marketers that are outside the company's control, and dependence on RP Management, LLC for all services because the company is externally managed. It also notes leverage risk, interest rate and foreign currency exposure, and the risk that the company could be treated as an investment company under the U.S. Investment Company Act if its royalty exemptions were restricted.
06—Continue